Abstract Non-Hodgkin lymphomas (NHLs) are often present outside the lymph nodes. Although primary extranodal NHLs form a substantial part of all NHLs, reports on oral primary extra nodal NHLs are rare. Mantle cell lymphoma (MCL) is a rare B-cell neoplasm that has only recently been defined as a distinct entity. MCL of the oral cavity is an uncommon diagnosis. Most oral MCLs occur in an elderly male population and have a possible predilection for the palate. The microscopic diagnosis can be challenging, given its similar appearance to other small cell lymphomas, requiring a comprehensive immunohistochemical panel for the accurate diagnosis. Like MCL occurring in other sites in the body, the prognosis and outcome of oral MCL appears to be poor.
Introduction
Malignant lymphomas are a diverse group of malignancies arising from the lymphoreticular system [1] . They constitute the third most common neoplasm in the head and neck region after Squamous cell carcinoma and Salivary gland tumors [2] . Hodgkin's disease and Non-Hodgkin's lymphoma (NHL) are the two main types of malignant lymphomas. NHL comprises approximately 5 % of head and neck malignancies and displays a wide range of appearances comparable with Hodgkin's disease [2] . Non-Hodgkin's lymphoma (NHL) arises primarily within the lymph nodes, but approximately 24 % affect extranodal locations [3] . The most frequent extranodal sites include the gastrointestinal tract, skin, bones and Waldeyer's ring. The reported incidence of NHL in the oral cavity ranges from 0.1 to 5 % [3] . NHL may occur within the soft tissue or the osseous structures in the oral cavity, affecting the paranasal sinuses, gingiva, palate, tongue, floor of the mouth, buccal mucosa, salivary glands or cheeks [4] .
Mantle cell lymphoma (MCL) is a lymphoid malignancy of B cells of the mantle zone or the primary lymphoid follicle. In 1992, Banks et al. [5] introduced the term MCL, which was subsequently adopted by the WHO in 2001 and is currently the favored nomenclature [6] . MCL is an uncommon B-cell malignancy and typically occurs in middle-aged to older adults with marked male predilection [7] . Recognition of MCL and its differentiation from other non-Hodgkin lymphoma (NHL) subtypes is important because of both the variable prognosis and changing therapeutic regimens. Few cases of MCL arising within the oral cavity have been reported. To date, there have been only nine reported cases in the English literature [8] . All the reported cases reported have been unifocal lesions of the oral cavity. We present here a case of multifocal MCL that presented with an indolent appearance. dental evaluation. Intra oral examination revealed three different lesions intra orally (bilaterally on the buccal mucosa and on the palate). The lesions on the buccal mucosa presented as a smooth, painless, ovoid shaped well circumscribed homogenous lesion bilaterally. The covering mucosa was normal in color without ulceration or inflammatory signs. The swelling on the left side ( Fig. 1 ) was larger and measured approximately 4 9 3 cms in size and extended anteriorly from the commissure of the lip, posteriorly to the retromolar region. The swelling on the right side ( Fig. 2 ) was smaller measured approximately 3 9 2 cms in size. On palpation the lesions of the buccal mucosa were firm, non tender, non compressible, non reducible, freely movable over the underlying tissues and exhibited no fluctuation or crepitus. The palatal swelling was localized and located in the midline at the junction of hard and soft palate (Fig. 3) . The swelling was pear shaped, with normal overlying mucosa and a corrugated surface. There was no clinical evidence of enlargement of the cervical lymph nodes. The patient's previous medical history was noncontributory. Differential diagnosis included Minor Salivary Gland Lesion, Fibroma, Reactive lymphoid lesion of the oral cavity, Lipoma, Fibrolipoma etc. Radiographic evaluation of the palatal lesion did not reveal any resorption of the surrounding palatal bone (Fig. 4) . Ultrasound examination of the neck and salivary glands neither revealed any gross enlargement nor any focal echogenic lesion. Ultrasound abdomen did not reveal any gross abnormality except for mild splenomegaly. Chest radiograph did not demonstrate any alveolar opacities or mediastinal and intrathoracic lymph node involvement. Fig. 1 The buccal mucosal lesion on the left side measured approximately 4 9 3 cms in size presenting as a smooth, ovoid shaped well circumscribed homogenous lesion without surface ulceration or inflammation Fig. 2 The buccal mucosal lesion on the right side swelling measured approximately 3 9 2 cms in size presenting as a smooth, ovoid shaped well circumscribed homogenous lesion Fig. 3 The palatal swelling located in the midline at the junction of hard and soft palate appeared pear shaped, with normal overlying mucosa and a corrugated surface
Biopsy
The patient was taken up for biopsy of the lesions of buccal mucosa and the palate under GA. Excisional biopsy of the lesions of the buccal mucosa was carried out and an incisional biopsy of the palatal lesion was done. The gross surgical specimen (Fig. 5 ) consisted of three bits of soft tissue with the largest sample measuring 3 9 2 9 1.5 cms. Grossly, the mass appeared relatively avascular and fibrotic in consistency with a corrugated external surface showing areas of congestion and papillary excrescences.
Post Operative Follow Up
Post operative healing of the buccal mucosa and the palate were uneventful. However patient refused any further treatment and was subsequently lost to follow up.
Histopathological Findings
Excised material comprised of squamous epithelial lined mucosa, salivary tissue, muscle and adipose tissue. Submucosal proliferations of monomorphic population of atypical lymphoid cells of centrocytic and centroblastic morphology were seen (Figs. 6, 7). Scattered immunoblasts were also noted, with scattered area of mitotic activity. Diffuse lymphocytic infiltrate involving the parenchyma of the surrounding minor salivary gland tissue was also seen. Based on the light microscopic finding a lymphoproliferative disorder of MALT type was suspected.
Immunohistochemistry
Immunohistochemical examination performed on paraffinembedded tissue confirmed a CD20-positive B-cell infiltrate ( Fig. 8 ) which co-expressed CCND1 (Cyclin D-1), CD5 ( Fig. 9 ) and CD43 ( Fig. 10 ). The lesion was positive for CD20, CD5 and CCND1 ( Fig. 11 ) but negative for CD10, Bcl-6 and CD23. Neither fluorescence in situ hybridization nor polymerase chain reaction studies were performed in our case, because it is well documented that the final common endpoint of this cytogenetic translocation is CCND1 protein over expression. We chose to use immunohistochemical staining for the CCND1 protein, owing to its high sensitivity and specificity for MCL.
Discussion
NHL is a heterogeneous group of lymphoproliferative malignancies that are much less predictable than HD and have a far greater predilection to disseminate to extranodal tissues [9] . Most such lymphomas have been shown to be predominantly of B-cell lineage, and may involve both osseous and soft tissues [10, 11] .
Although head and neck lymphomas are relatively common; the occurrence of NHL in the oral mucosa is rare and not well-documented. Moreover it is uncommon for NHL to appear first or only orally [8] . Although any type of The gross surgical specimen appeared relatively avascular and fibrotic in consistency with a corrugated external surface NHL may present intraorally, the most common are largecell lymphoma and small lymphocytic lymphoma. [12, 13] .In the oral cavity the most common site of involvement is the palate [14] . Oral lesions may appear as an erythematous, painless enlargement, often with surface ulceration secondary to trauma [13] . NHL rarely presents with deep oral ulceration. The present case presented as a painless enlargement of the buccal mucosa without surface ulceration or erythema bilaterally and as a proliferative lesion at the junction of hard and soft palate.
At least two-thirds of NHL cases present with non tender lymph node enlargement persisting for greater than 2 weeks [15] . Systemic signs and symptoms include fever of unknown origin (C38°C), unexplained weight loss (C10 % over 6 months), drenching night sweats, visceral pain and malaise; collectively these are known as ''B symptoms'' and are identified in 40 % of new cases. In the oral cavity, lymphomas usually present as an extranodal, soft, asymptomatic lesion, hardly ever being accompanied by 'B' symptoms [13] .
Mantle cell lymphoma is an uncommonly encountered B-cell neoplasm characterized by small-to-medium-sized lymphoid cells [5, 6] . Variety of diagnostic terminologies have been used to describe the entity like Intermediate Lymphocytic Lymphoma, Centrocytic Lymphoma, and Mantle Zone Lymphoma [8] . MCL accounts for between 6 and 10 % of all B-cell lymphomas. Although the majority of MCLs occur in lymph nodes, many patients have extranodal involvement, with the spleen, gastrointestinal tract, and Waldeyer ring being the most commonly affected sites [7, 16] . Despite recent data showing an increase in the incidence of MCL to 0.55/100,000 persons/yr, it remains one of the least common B-cell malignancies. Although as a group, NHL is a common malignancy presenting within the head and neck region, involvement of the head and neck by MCL is unusual, and the primary presentation of MCL within the oral cavity is very rare. [8] All the reported cases in the oral cavity have been unifocal lesions involving either the palate, tongue or the floor of the mouth. Our case had a multifocal presentation with bilateral involvement of the buccal mucosa and also the palate.
The majority of the oral MCL cases reported have occurred in men. The cases generally occurred in sixth to eight decade with mean age at the time of presentation of 71 years [8] . Majority of patients reported in the literature present with a unifocal mass without any contributory medical history or accompanying ''B Symptoms''. Our case presented as a multifocal indolent sub mucosal masses of the oral cavity without any accompanying 'B'-type symptoms.
MCLs are currently believed to originate from mature but naive B cells, i.e., B cells expressing rearranged immunoglobulin genes, but not yet having encountered antigen. The mature B cells that have not yet encountered antigen migrate from bone marrow into lymph nodes and primary B-cell follicles, in which the naive B cell makes initial antigenic contact in cognate interaction with T cells and interdigitating dendritic cells. These antigen-activated B cells subsequently form a germinal center (GC). The B cell populating the dark zone of a GC is the Centroblast that after a proliferative phase acquires the phenotype of a Centrocyte. In addition, they express phenotypical markers such as CD19, CD20, CD22 and CD79a/b, but lack CD10 and generally CD23. The most characteristic nuclear marker of MCL is the over expression of Cyclin D1(CCND1), which is rarely seen in other types of NonHodgkin lymphoma, although CCND1 has been shown to be associated with several types of solid tumors. CCND1 promotes the G 1 to S-phase transition by binding to cyclindependent kinases and is probably one of the main features contributing to the malignant behavior of MCL [17] .
Morphologically, MCL is characterized by a monomorphic lymphocytic infiltrate with a diffuse, vaguely nodular or expanded mantle zone pattern [18] . Cytologically similar to centrocytes, the neoplastic lymphocytes are small to medium, with nuclear contours ranging from slight to markedly irregular. The nuclei have dispersed chromatin without prominent nucleoli. Large transformed lymphocytes are usually absent. Hyalinized small blood vessels and scattered epithelioid histiocytes are frequently observed. Reactive plasma cells can be identified. There are several morphologic variants reported in the literature. The blastoid variants are the most common; in fact, they are further sub classified into classic and pleomorphic types [19] . The former is composed of cells with immature, blastic chromatin patterns and a high mitotic rate. The latter consists of cells that with a Giemsa stain have large oval or cleaved nuclei, some with prominent nucleoli surrounded by pale cytoplasm.
Immunophenotypically, the neoplastic lymphocytes usually express CD5, CD20, CD43 and FMC-7, but not CD10 or Bcl-6 [18, 20] . The lymphocytes are typically negative for CD23 expression, but on occasion, they may be weakly positive. All lymphocytic specimens typically express CYCLIN D1 (Bcl-1), including the rare specimen that is CD5-negative [21] . The chromosomal translocation t (11; 14) (q13; q32), which results in the juxtaposition of the CCND1 (Bcl-1) gene locus to the Ig heavy chain promoter, is a characteristic but not universal molecular feature of this lymphoma subtype [21] . This translocation occurs between the immune globulin heavy chain and the CYCLIN D1 (Bcl-1) genes [22] leading to the overexpression of Bcl-1 protein. If the morphologic findings and immunophenotyping results are deemed diagnostically inconclusive, Conventional Cytogenetics, Southern blot analysis or Fluorescence In Situ Hybridization can be used to detect t (11; 14) . Fluorescence In Situ Hybridization has a sensitivity approaching 100 % and therefore is the preferred method [23] .
In our patient, the morphologic findings and immunophenotypic pattern of the neoplastic lymphocytes share characteristics of MCL occurring in lymph nodes and extranodal sites. The primary differential diagnosis relevant to this case included members of the small B cell lymphoma family other than MCL; this family consists of small lymphocytic lymphoma and follicular lymphomas (FL). Where the diagnostic options show significantly common microscopic features, the performance of adequate immunophenotyping/genotyping is critical to establish an accurate diagnosis. For instance, FL usually has a nodular pattern, sometimes with focal diffuse areas and has variable numbers of small cleaved cells and centroblasts. The neoplastic lymphocytes usually express CD10, CD20, and Bcl-2; typically lack CD5, CD43 and Bcl-1 expression; and exhibit t (14; 18) (q32; q21) genetic lesions [24] . Occasionally, neoplastic lymphocytes express CD23. MALT lymphoma usually presents in an expanded marginal zone pattern but less commonly with a follicular pattern and is composed of a heterogeneous lymphoid population including centrocyte-like small cells, monocytoid lymphocytes, large transformed lymphocytes, plasmacytoid lymphocytes, and plasma cells. The neoplastic lymphocytes usually express CD20; frequently express Bcl-2; occasionally express CD43; do not express CD5, Bcl-1, CD10, or CD23; and may exhibit t(11;18)(q21;q21) or trisomy three as genetic lesions [24] . B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma usually presents in a diffuse pattern with proliferation centers and less commonly with an interfollicular pattern and is composed of small lymphocytes and prolymphocytes/ paraimmunoblasts, with the latter concentrated in the proliferation centers. The neoplastic lymphocytes usually express CD5, CD20, CD23 and CD4 but not CD10 or Bcl-1 and may exhibit trisomy 12 or 13q deletion as genetic lesions [24] .
Although MCL is often a relatively slow growing lymphoma, the disease tends to be relentless with minimal sustained response to all treatment modalities [25] . Prognosis is generally worse than most other NHL, with a median survival of only 3 years [25] . Reported treatments in the literature have included combination chemotherapy alone, combination chemotherapy and radiotherapy or no treatment/observation. The small number of patients with early stages of disease may potentially be cured by modified extended or involved field radiation. In advanced stages combination chemotherapy represents only a noncurative treatment option. Different chemotherapeutic regimens have been employed with an overall response rate of approximately 70 %, with complete remissions in up to 20-40 % of cases. Conventional Combination chemotherapy CHOP regimen (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) or COP(Cyclophosphamide, Vincristine and Prednisone) regimen have shown an overall response rate of 84 and 89 %, with a median overall survival of 32 and 37 months, respectively. Higher response rates of more than 90 % could be achieved by a doseintensified approach applying an alternating regimen of Hyper-CVAD (fractionated Cyclophosphamide, Vincristine, Doxorubicin and Dexamethasone) with high-dose Cytarabine and Methotrexate [25] .
In recent years, various studies have investigated the efficacy of anti-CD20 antibody Rituximab in MCL. Monotherapy with Rituximab showed only a moderate activity, with partial response rates of approximately 20-40 %. In contrast, the combined immunotherapy (Rituximab and CHOP) achieved remarkably high overall and complete response rates (96 and 48 %), suggesting a chemosensitizing effect of Rituximab [26] . One of the other options, established in the meantime, in the treatment of MCL is Myeloablative therapy followed by autologous stem cell transplantation. This approach significantly improves the progression-free survival and may partially overcome the therapeutic dilemma of MCL [24] . Newer therapeutic modalities have emerged in the form of Flavopiridol (a specific inhibitor of the cyclin-dependent kinase), Bortezomib (a proteasome inhibitor highly effective against MCL derived cell lines), which have shown substantial antitumor activity and a highly chemosensitizing effect, which might be more effective in combination with chemotherapy [27] .
Conclusion
Clinicians may occasionally encounter indolent multifocal lesions of the oral cavity. An orderly approach and formulation of a reasonable differential diagnosis is imperative keeping in mind that unusual lesions like malignant lymphomas can occur in the oral cavity. We have described here the first case of a MCL occurring in the oral cavity with a multi focal presentation. This entity should be recognized and adequately diagnosed because it may have a more aggressive clinical course than other members of the small B-cell lymphoma family. A detailed morphologic evaluation with thorough immunophenotyping and genotyping is essential for an accurate diagnosis.
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